ASPIRIN POWDER COMPLEX FOR SOLUTION 3547.5 MG PACKAGE
ASPIRIN POWDER COMPLEX FOR SOLUTION 3547.5 MG PACKAGE - 10 PCS
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
International non-proprietary or grouping name
Acetylsalicylic acid + Phenylephrine + Chlorphenamine.
Powder effervescent for the preparation of oral solution.
Each bag contains
Active ingredients: acetylsalicylic acid - 500 mg, phenylephrine hydrotartrate - 15.58 mg, chlorphenamine maleate - 2.00 mg;
Excipients: anhydrous citric acid 1220 mg, sodium bicarbonate
1709.6 mg, lemon flavor 100 mg, quinoline yellow dye (E 104) 0.32 mg.
A mixture of crystalline powders from almost white to white with a yellowish tinge.
Means to eliminate the symptoms of acute respiratory infections and "cold" (NSAIDs + alpha adrenomimetik + H1-
histamine receptor blocker). ATX code: R05X Pharmacological properties
Combined medication, the action of which is due to its active ingredients.
Acetylsalicylic acid (ASA) It has analgesic, antipyretic anti-inflammatory effect, which is caused by inhibition of cyclooxygenase enzymes involved in the synthesis of prostaglandins. Acetylsalicylic acid inhibits platelet aggregation, blocking the synthesis of thromboxane A2.
Phenylephrine is a sympathomimetic and, having a vasoconstrictor effect, reduces swelling of the mucous membranes of the nasal sinuses, as a result of which breathing is facilitated. Chlorphenamine belongs to the group of antihistamines, relieves symptoms such as sneezing and tearing.
Indications for use
Use to relieve symptoms of “colds”, acute respiratory viral infections, flu, such as: fever and chills, headache and muscle pain, runny nose and / or nasal congestion, sore throat and sneezing.
Hypersensitivity to acetylsalicylic acid and other NSAIDs or other components of the drug.
Erosive and ulcerative lesions of the gastrointestinal tract (in the acute phase), chronic or recurrent ulcers.
Asthma caused by taking salicylates or other NSAIDs.
Blood clotting disorders, such as hemophilia, hypoprothrombinemia.
Severe abnormal liver and / or kidney function.
Nasal polyposis associated with bronchial asthma and acetylsalicylic acid intolerance.
Enlargement of the thyroid gland.
Combined use with oral anticoagulants.
Combined use with monoamine oxidase inhibitors, including 15 days after discontinuation.
The combined use of Methotrexate at a dose of 15 mg per week or more.
Pregnancy (I and III trimester), breastfeeding period.
The drug is not prescribed to children under 15 years of age with acute respiratory diseases caused by viral infections, due to the risk of Reye's syndrome (encephalopathy and acute fatty liver with acute development of liver failure).
Use in patients with lung and kidney disease, with glaucoma, pheochromocytoma, cardiovascular diseases, diabetes mellitus, prostatic hypertrophy, with anemia.
Dosage and administration
Dissolve the contents of the bag in a glass of water room temperature. Take inside after eating.
Adults and children over 15 years: one sachet every 6-8 hours.
The maximum daily dose - 4 bags, the interval between doses of the drug should be at least 6 hours.
The duration of treatment (without consulting a doctor) should not exceed 5 days when prescribed as an anesthetic and more than 3 days as an antipyretic.
Acetylsalipilic acid The body as a whole: hyperhidrosis.
Gastrointestinal: nausea, dyspepsia, vomiting, gastric and duodenal ulcers; Gastrointestinal bleeding, including hidden (black stools).
Allergic reactions: urticaria, eczematous skin rash, angioneurotic edema (angioedema), rhinitis, bronchospasm and shortness of breath.
Hematopoietic system: hypoprothrombinemia.
Central nervous system and sensory organs: dizziness, tinnitus, headache, hearing loss.
Urinary system: renal failure, acute interstitial glomerulonephritis.
In rare cases (<1%), toxic liver damage, especially in patients with juvenile rheumatoid arthritis; anemia, Reye's syndrome in children.
Central nervous system and sensory organs: headache, dry mouth, insomnia, nausea, irritability, anxiety.
In rare cases:
Central nervous system: severe headache, inappropriate behavior.
Cardiovascular system: high blood pressure, tachycardia.
Urinary system: painful or difficult urination.
The body as a whole: dry mouth, dry mucous of the mouth and nose, disturbed accommodation (blurred vision).
Cardiovascular system: tachycardia.
Urinary system: urinary retention, difficulty and pain when urinating.
Central nervous system and sensory organs: attention disorder, drowsiness, dizziness. In children and elderly patients are possible: lethargy, agitation, dizziness, anxiety, irritability.
If any adverse reactions occur, stop taking the drug and consult a doctor.
Symptoms: nausea, vomiting, tinnitus, impairment of hearing and vision, rapid breathing, severe headache, imbalance, marked drowsiness, and heart rhythm disturbances.
Treatment: gastric lavage, the appointment of Activated carbon, symptomatic therapy.
Interaction with other drugs
Combination with Methotrexate at a dose of> 15 mg per week is contraindicated. Combinations of drugs that are used with caution:
Methotrexate in a dose of less than 15 mg / week: The simultaneous use of drugs increases the hematologic toxicity of methotrexate due to the fact that NSAIDs in general reduce the renal clearance of methotrexate, and salicylags, in particular, displace it from the association with plasma proteins.
Anticoagulants (coumarin, heparin): while taking ASA and indirect anticoagulants, the risk of bleeding increases due to the suppression of platelet function, damage to the mucous membrane of the stomach and duodenum, and the displacement of oral anticoagulants from their association with plasma proteins.
Other NSAIDs with salicylates at a high dose (at a dose of 3 g / day or more): with the simultaneous use of drugs because of the synergistic effect, the risk of ulceration of the mucous membrane of the gastrointestinal tract and bleeding increases.
Uricosuric drugs (probenecid, sulfinpirazon): the therapeutic effect of uricosuric drugs is reduced due to competitive tubular elimination of uric acid.
Digoxin: with the simultaneous use of drugs increases the concentration of Digoxin in the plasma by reducing its excretion.
Antidiabetic drugs (insulin, sulfonylurea): the hypoglycemic effect is enhanced by the fact that high-dose ASA has hypoglycemic properties and displaces the sulfonylurea from the bond with plasma proteins.Thrombolytic / anti-platelet drugs of other classes (ticlopidine): the risk of bleeding increases.
Diuretics in combination with ASA at a dose of 3 g / day or more: reduced glomerular filtration, due to a decrease in the synthesis of prostaglandins in the kidneys.
Systemic glucocorticosteroids (GCS) with the exception of Hydrocortisone (used to treat Addison's disease): with simultaneous use of drugs, the concentration of salicylates in the blood decreases because GCS increases the elimination of salicylates. Angiotensin-converting enzyme (ACE) inhibitors: with the simultaneous use of ACE inhibitors and ASA at a dose of 3 g / day or more, a decrease in the hypotensive effect of ACE inhibitors is observed, due to a decrease in glomerular filtration.
Valproic acid: ASA breaks the association of valproic acid with plasma proteins, resulting in increased toxicity.
Alcohol: when combined with ASA, the damaging effect on the mucous membrane of the gastrointestinal tract increases and the bleeding time is prolonged.
Monoamine oxidase inhibitors (MAO inhibitors): with simultaneous use of phenylephrine and MAO inhibitors (antidepressants - tranylcypromine, moclobemide; antiparkinsonian drugs - selegilin) severe side effects are possible in the form of intense headache, high blood pressure and body temperature. Beta-blockers - with simultaneous use may increase blood pressure (hypertension) and severe bradycardia.
Sympathomimetics: with simultaneous use, the effect of sympathomimetics on the CNS and cardiovascular system is enhanced. Perhaps arousal, irritability, insomnia.
Inhalation anesthetics: the use of filylephrine before inhalation anesthesia increases the risk of heart rhythm disturbances. Treatment with phenylephrine should be discontinued a few days before the planned surgical treatment. Rauwolfia alkaloids - with simultaneous use may decrease the therapeutic effect of phenylephrine.
Caffeine: when applied simultaneously, the therapeutic and toxic effects of caffeine may increase.
Indomethacin, Bromocriptine : in isolated cases with simultaneous use of phenylephrine with Indomethacin or bromocriptine severe arterial hypertension is possible.
Selective serotonin reuptake inhibitors: when used simultaneously with antidepressants of this group (fluvoxamine, paroxetine, sertraline), the body's sensitivity to sympathomimetics may increase as well as the risk of a serotonergic effect may increase.
Antihypertensive drugs from the group of sympatholytics, such as reserpine, guanethidine: phenylephrine reduces the hypotensive effect of these drugs.
Alcohol, hypnotic drugs, tranquilizers, antipsychotics (antipsychotics), neutral analgesics: Chlorphenamine may increase the inhibitory effect of these drugs on the central nervous system.
Anticholinergics (atropine, antispasmodics, tricyclic antidepressants, MAO inhibitors, anti-Parkinsonian drugs): Chlorphenamine enhances the anticholinergic effect of these drugs.
Acetylsalicylic acid can cause bronchospasm, an attack of bronchial asthma, or other hypersensitivity reactions. Risk factors are the presence of asthma, nasal polyps, fever, chronic broncho-pulmonary diseases, history of allergies (allergic rhinitis, skin rashes).
Acetylsalicylic acid may increase the tendency to bleeding, which is associated with its inhibitory effect on platelet aggregation. This should be considered when